Skip to main content
OpenTrials
Completed

NCT Number: NCT00796809

Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis

The goal of the project is to study the risk of coccidioidomycosis (valley fever) in patients receiving anti-TNF and other biologic agents for inflammatory arthritis in Tucson, Arizona.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Retrospective chart review of all patients with an inflammatory arthritis seen at the University Rheumatology clinic since January 2000.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All active patients with an inflammatory arthritis seen at the University of Arizona from January 2000

Exclusion criteria

  • None

Treatment and study plan

Primary outcomes

  1. Determine the incidence rate and calculate the risk of coccidioidomycosis in patients receiving various anti-TNF agents or other biologics, and patients not receiving these agents for their inflammatory arthritis

    Time frame: one year

Secondary outcomes

  1. To calculate the incidence density of coccidioidomycosis cases in patients receiving each drug.

    Time frame: One year

  2. To compare number of disseminated cases of coccidioidomycosis in each group

    Time frame: One year

Sponsors and collaborators

Lead sponsor

University of Arizona

Other

Collaborators

  • Centocor, Inc.

Registry information

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
Nov 24, 2008
Registry last updated
Dec 14, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.